Medicine & Life Sciences
Coronavirus
100%
Soft Tissue Infections
96%
WCK 5222
86%
Infections
79%
tedizolid
69%
T 91825
64%
Anti-Bacterial Agents
64%
Cefepime
64%
Linezolid
63%
Tazobactam
62%
Therapeutics
61%
Nontuberculous Mycobacterium Infections
60%
miltefosine
60%
Carbapenems
57%
Guidelines
54%
Pharmacokinetics
50%
Gram's stain
50%
Candidiasis
46%
Leprosy
45%
Bronchoalveolar Lavage
43%
Encephalitis
42%
Vancomycin
42%
Endocarditis
41%
Septic Shock
40%
Pharmacists
39%
Cystic Fibrosis
38%
Consensus
37%
Brain Diseases
37%
Case-Control Studies
37%
Bacterial Infections
37%
Transplant Recipients
36%
Pseudomonas aeruginosa
36%
Necrotizing Fasciitis
35%
Multiple Sclerosis
35%
Cerebrospinal Fluid
34%
Gastrointestinal Tract
34%
tazobactam drug combination ceftolozane
34%
Communicable Diseases
34%
Bacteria
33%
Tuberculosis
32%
Thigh
32%
Pneumonia
32%
Sepsis
32%
Hospital Emergency Service
31%
Pandemics
31%
Pharmaceutical Preparations
30%
Acanthamoeba
28%
Methicillin-Resistant Staphylococcus aureus
27%
Tazobactam Drug Combination Piperacillin
26%
Severe Acute Respiratory Syndrome
25%
Pediatrics
25%
Transplants
24%
Skin
21%
GS-5734
21%
terizidone
20%
Duration of Therapy
19%
Meropenem
19%
Systemic Inflammatory Response Syndrome
18%
Disease Eradication
18%
Anti-Infective Agents
18%
zidebactam
17%
Thioacetazone
17%
Rifamycins
16%
Escherichia coli
16%
bedaquiline
16%
Upper Gastrointestinal Tract
16%
Aminosalicylic Acid
16%
Bacterial Endocarditis
15%
In Vitro Techniques
15%
Clofazimine
14%
Medication Therapy Management
14%
Polysaccharides
14%
Sulfones
14%
Abscess
14%
Adrenal Cortex Hormones
14%
Global Health
14%
Cycloserine
14%
Peritoneal Dialysis
14%
North America
14%
Debridement
13%
Pyrazinamide
13%
Dapsone
13%
Latent Tuberculosis
12%
Ethambutol
12%
Odds Ratio
12%
Artificial Respiration
12%
Confidence Intervals
11%
Ertapenem
11%
Cohort Studies
11%
Isoniazid
11%
Macrolides
11%
Population
11%
Fluoroquinolones
11%
Health Services Needs and Demand
11%
Aminoglycosides
10%
Safety
10%
Early Diagnosis
10%
Lung
10%
Public Health
10%
Expert Testimony
10%